Latest Regulatory Milestones News

Page 2 of 102
The FDA has granted orphan drug designation to Neuren’s NNZ-2591 for neonatal hypoxic-ischemic encephalopathy, giving the programme potential US exclusivity and regulatory fee relief. The company is completing a juvenile animal safety study before targeting an IND submission in the first half of 2027.
Victor Sage
Victor Sage
2 Nov 2026
Emperor Energy has converted its rig arrangement into a binding full form contract, securing Valaris 107 for the Judith-2 appraisal well offshore Victoria in April 2027. The milestone reduces one immediate execution risk, but leaves further payments and the drilling outcome ahead.
Victor Sage
Victor Sage
2 Nov 2026
Percheron Therapeutics has received a US FDA Safe to Proceed letter for Vanderbilt Health to begin an investigator-sponsored trial of HMBD-002 in combination with venetoclax and azacitidine. The early-stage study will target up to 20 patients with relapsed or refractory AML or AML with MDS.
Ada Torres
Ada Torres
2 Nov 2026
Delorean’s flagship Salisbury bioenergy plant is 90% complete and now licensed to operate, while a proposed A$20 million Westpac facility could unlock its next major project. The catch is a quarterly operating cash outflow of A$2.52 million, leaving 2.52 quarters of funding on the company’s own calculation.
Victor Sage
Victor Sage
30 Oct 2026
GoldArc Resources has cleared a key regulatory hurdle for Mt Stirling, completed grade control drilling at Mt Stirling Well and continued to find high-grade gold across its Leonora projects. The company ended September with A$2.831 million in cash and A$2.5 million of unused funding facilities, but a mining start date remains unsettled.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Dome Gold Mines has reached a regulatory milestone at its Sigatoka heavy mineral sands project, but remains suspended from trading with no cash on hand and its annual audit unfinished. The company is seeking up to A$3 million through convertible notes while it negotiates funding for valuation work and working capital.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Control Bionics has begun converting its expanded product and regulatory pipeline into revenue, while a completed $9.75 million capital raising gives the company a larger cash buffer. The next test is whether partner-led sales and NeuroStrip trial conversions can reduce its cash burn as planned.
Victor Sage
Victor Sage
29 Oct 2026
Avecho has resumed recruitment for the final cohort of its pivotal Phase III insomnia trial after an interim review supported continuing at the original 519-participant target. The biotechnology company is also pursuing international licensing while holding $5.3 million in cash.
Ada Torres
Ada Torres
28 Oct 2026
Nexsen is pursuing a second Group B Streptococcus device through a proposed FlashDx joint venture while upgrading StrepSure after interim clinical data shifted its US FDA submission target to early 2027. The diagnostics developer ended September with $3.56 million in cash, equivalent to about four quarters of funding at the latest operating cash-flow rate.
Ada Torres
Ada Torres
28 Oct 2026
OncoSil Medical delivered sharper commercial growth and a string of regulatory milestones in FY26, but the oncology device company remains heavily loss-making and dependent on future sales or fresh capital. Revenue rose 44% to $1.68 million while operating cash outflow reached $10.47 million.
Victor Sage
Victor Sage
27 Oct 2026
TMK Energy has posted record quarterly gas production at its Mongolian pilot project while securing regulatory acceptance of a formal gas discovery. The milestone opens an appraisal pathway, but reserves, a production licence and longer-term funding remain unresolved.
Victor Sage
Victor Sage
26 Oct 2026
Invex Therapeutics has agreed to acquire New Zealand biotech Rekover Therapeutics for shares and performance rights, adding a planned Phase 2a multiple sclerosis trial to its neurology portfolio. The transaction is paired with a $10 million placement, but would substantially expand the company’s share count and requires shareholder approval.
Ada Torres
Ada Torres
26 Oct 2026

Browse the archive

Full archive